Watchlist Price Alert

Regulus Therapeutics Inc. (RGLS)

NASDAQ: RGLS · Real-Time Price · USD

8.25

0.14 (1.73%)

At close: Jun 16, 2025, 3:59 PM

8.24

-0.12%

After-hours: Jun 16, 2025, 07:30 PM EDT

1.73% (1D)

Bid	7.99
Market Cap	571.18M
Revenue (ttm)	n/a
Net Income (ttm)	-47.52M
EPS (ttm)	-0.68
PE Ratio (ttm)	-12.13
Forward PE	-7.63
Analyst	Hold

Ask	8.24
Volume	1,042,012
Avg. Volume (20D)	2,120,150
Open	8.16
Previous Close	8.11
Day's Range	8.07 - 8.28
52-Week Range	0.83 - 8.35
Beta	0.37

About RGLS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RGLS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RGLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+136.8%

Regulus Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

2 months ago

+16.28%

Regulus Therapeutics shares are trading higher after the company announced topline results from the phase 1b MAD study of Farabursen for autosomal dominant polycystic kidney disease.

News

1 month ago · businesswire.com

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...

1 month ago · benzinga.com

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.

1 month ago · benzinga.com

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.

1 month ago · businesswire.com

RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Regulus Therapeutics Inc. (NASDAQ: RGLS) to Novartis AG in cash is fair to Regulus shareh...

1 month ago · businesswire.com

Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to l...

1 month ago · reuters.com

Novartis to buy Regulus Therapeutics for up to $1.7 billion

Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.

1 month ago · zacks.com

Should You Buy Regulus (RGLS) After Golden Cross?

Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RGLS's 50-day simple moving average broke out above...

2 months ago · benzinga.com

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease

Regulus Therapeutics Inc. RGLS released topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen (RGLS8429) autosomal dominant polycystic kidney disease (ADPKD) o...